| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 3, 2026Next | Q3 2026 | Before market open | 1.90 | 2.06 B |
Sep 1, 2026
Zimmer Biomet sees strong constant currency sales growth driven by transformation, R&D and M&A.
Aug 28, 2026
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026. The cash dividend of $0.24 per share is payable on or about October 30, 2026 to stockholders of record as of the close of business on September 30, 2026.
Aug 20, 2026
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...
Aug 17, 2026
Supported by real market data through Q4 2025 and 10-year projections, this study delivers a granular evaluation across metal and polymer part categories (prototypes, tooling, end-use production components) and major consuming end-markets, including aerospace giants (GE Aerospace, SpaceX, BAE Systems), medical leaders (Stryker, Zimmer Biomet, Align Technologies), and automotive/tech pioneers (Tesla, Apple, Nvidia).Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) -- The "AM Applications Analysis: Parts Pro
Aug 14, 2026
Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform
Aug 12, 2026
Management raised full-year guidance on strong hip and technology segment growth.
Aug 10, 2026
Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and raises the price target from $83 to $100.
Aug 9, 2026
Zimmer Biomet (NYSE:ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constan
Aug 7, 2026
Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and raises the price target from $92 to $106.
Zimmer Biomet Holdings (ZBH) just paired stronger than expected quarterly results with a guidance increase, as management pointed to solid execution in U.S. hip and technology lines and progress in its sales force restructuring. See our latest analysis for Zimmer Biomet Holdings. Zimmer Biomet Holdings' recent guidance lift and Q2 beat come after a period of mixed returns, with the share price at US$97.19 and a 90-day share price return of 18.05%. However, the 5-year total shareholder return...
Zimmer Biomet Holdings is back in focus as analysts fine tune their price targets around recent research and earnings news. Targets such as US$110, US$95 and US$93 reflect a mix of supportive and cautious views on how the current share price lines up with execution and growth expectations. As you read on, you will see how these moves fit into the evolving narrative and what to watch next to stay on top of sentiment around Zimmer Biomet Holdings. Stay updated as the Fair Value for Zimmer...
Aug 6, 2026
RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and raises the price target from $101 to $110.
